This could be read as growing pre-nuptial synergy between Cipla and the Serum Institute of India. Or maybe the duo's next step in their "relationship" is purely an extension of a previous alliance and one which will see Cipla step up its indirect interest in vaccines play to the Indian market.
Cipla, announced on 27 May that it had signed a pact to exclusively market Serum's flu vaccine Nasovac-S in India....